EINSTEIN-PE Trial New Engl J Med 2012;366:1287-97 (April 5) Study Type: POEM Purpose: Traditional treatment for PE has consisted of an injectable heparin or LMWH with bridging warfarin. This treatment has always had its issues with delays in hospital stay and monitoring. The Einstein trial evaluated using rivaroxaban alone to treat PE. This approach has been successful for treatment and prevention of acute DVT. Duration: n = 4832, 4 years for randomization at 263 centers in 38 countries, most patients treated 9 mths Trial Design: Randomized, open-label, noninferior trial, intention-to-treat. Rivaroxaban 15 mg twice daily for 3 weeks, then 20 mg daily vs. enoxaparin 1 mg/kg twice daily for at least 5 days and continued until INR was >2 on 2 consecutive days + warfarin or acenocumarol within 48 hours of start. NSAIDs discouraged. Clopidogrel (75 mg/day) and or aspirin (no more than 100 mg daily) was allowed. Patients: 58 years old, 50% male, 85% weighed in the range of 50 to 100 kg, 85% had CrCl 50 to normal, 10% had CrCl < 50, 87% had PE documented by spiral CT, 12% by VQ scan, 55% were of the intermediate form and 25% extensive involving more than 25% of the lung with multilobes, 89% were hospitalized, 13% to ICU, 4 days from symptoms to randomization, 65% cause unknown or unprovoked, 17% recent surgery, 16% immobilization, 9% estrogen, 4% cancer, ~20% had a previous VTE. Inclusion: legal age, acute symptomatic PE with objective confirmation Exclusion: any previous heparin or LMWH for 48 hours or more than a single dose of warfarin, thrombectomy, filter, fibrinolytic agent, CrCL < 30, liver disease, 3x normal ALT's, endocarditis, active bleeding, SBP > 180/DBP > 110, use of strong CYP 3A4 inhibitors (protease inhibitors, ketoconazole) or inducers (carbamazepine, phenytoin), pregnancy Outcome Events: Primary outcome was symptomatic, recurrent VTE (DVT or fatal/nonfatal PE).
1.
Are Major bleeding = Hb reduction of 2 gm, need of 2 units of blood, intracranial, retroperitoneal, contributed to death Clincally relevant nonmajor bleed = bleeding not meeting the major bleeding criteria, but needed intervention
